175 related articles for article (PubMed ID: 28580853)
1. [Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the Polycythemia vera patients].
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Kellner Á; Karádi É; Valasinyószki E; Udvardy M; Egyed M
Orv Hetil; 2017 Jun; 158(23):901-909. PubMed ID: 28580853
[TBL] [Abstract][Full Text] [Related]
2. [Development of the registry for Philadelphia-negative chronic myeloproliferative neoplasia in Hungary].
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Udvardy M; Egyed M
Orv Hetil; 2016 Jan; 157(3):98-103. PubMed ID: 26750731
[TBL] [Abstract][Full Text] [Related]
3. A potentially new thromboembolic event scoring system in polycythaemia vera patients: An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia register.
Karadi E; Dombi P; Korom VG; Kovacs E; Herczeg J; Andrikovics H; Illes A; Demeter J; Homor L; Udvardy M; Egyed M
Eur J Haematol; 2023 Aug; 111(2):263-270. PubMed ID: 37203365
[TBL] [Abstract][Full Text] [Related]
4. [An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the essential thrombocythaemic patients].
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Udvardy M; Karádi É; Kellner Á; Egyed M
Orv Hetil; 2017 Jan; 158(3):111-116. PubMed ID: 28110571
[TBL] [Abstract][Full Text] [Related]
5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
6. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
7. [Epidemiologic features of Philadelphia-negative chronic myeloproliferative disorders in Szabolcs-Szatmár-Bereg county, Hungary. Analysis of data of a 33-year period].
Jakó J; Szerafin L
Orv Hetil; 2017 Apr; 158(15):572-578. PubMed ID: 28393599
[TBL] [Abstract][Full Text] [Related]
8. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
9. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
10. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.
Gianelli U; Bossi A; Cortinovis I; Sabattini E; Tripodo C; Boveri E; Moro A; Valli R; Ponzoni M; M Florena A; F Orcioni G; Ascani S; Bonoldi E; Iurlo A; Gugliotta L; Franco V
Mod Pathol; 2014 Jun; 27(6):814-22. PubMed ID: 24201120
[TBL] [Abstract][Full Text] [Related]
11. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
12. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
13. Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D; Mascarenhas J
Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.
Ebid GT; Ghareeb M; Salaheldin O; Kamel MM
Int J Clin Exp Pathol; 2015; 8(9):11555-9. PubMed ID: 26617890
[TBL] [Abstract][Full Text] [Related]
16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of polycythemia vera in Cte d'Or (Burgundy).
Carli PM
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):147-9. PubMed ID: 8036130
[TBL] [Abstract][Full Text] [Related]
18. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.
Johansson P; Kutti J; Andréasson B; Safai-Kutti S; Vilén L; Wedel H; Ridell B
J Intern Med; 2004 Aug; 256(2):161-5. PubMed ID: 15257729
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and treatment of polycythaemia vera: state of the art].
Marton I; Simon Z; Borbényi Z
Orv Hetil; 2016 Oct; 157(44):1743-1751. PubMed ID: 27796129
[TBL] [Abstract][Full Text] [Related]
20. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
